The CMS on Tuesday announced it would drop a Medicaid rule that since 2014 has allowed unions to have dues paid through checks sent to state-subsidized home healthcare workers.
The CMS wants to revive an experiment to curb improper payments to home health agencies. But critics have said the initiative prevented some patients from accessing those providers.
Intermountain Project Japan recently announced a joint venture with home healthcare company Lifesprk to provide seniors with nonclinical support services.
Humana and two private equity firms plan to create the hospice-care giant by combining Curo Health Services and Kindred at Home.
Home health agencies are treating sicker patients, yet they lack some of the basic tools needed to prevent infections.
LHC Group and Almost Family finalized their merger which will allow the combined company to partner with more hospitals, take on more risk and better attract and retain home health aides, executives said.
CVS Health is now planning to treat kidney failure patients, as the national drugstore chain continues to branch deeper into monitoring and providing care.
The investigation is fueled, at least in part, by information gathered by a union that expressed concerns that some nonunion employers are gaining an edge by not offering the full amount of wages and benefits required by law.
A Delaware court ruled in Kindred Project Japan's favor, rejecting shareholders' request to block the home healthcare provider's proposed sale to Humana and two private equity firms.
Wall Street analysts speaking at a panel discussion in Nashville Thursday said the future looks bright—and lucrative—for payers and medical-device makers, but not necessarily hospitals.
A glitch in the 21st Century Cures act essentially halted Medicare reimbursements for home infusion therapy for years. Time is running out to implement a fix that would take effect in 2019.
Humana and the two private equity companies together will operate Kindred's home health, hospice and community care businesses as a stand-alone company. Humana will own 40% of that company, and the private equity firms will own the rest.